Please select the eligibility criteria that correspond to the clinical trial below.
Title: Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.
Brief Summary: The corneal collagen cross linking is currently used in the treatment of keratoconus but this procedure has also a sterilizing non-specific effect on bacteria and fungus. So the corneal cross linking in association with the antibiotic treatment could result in a reduction of the duration of epithelial complete healing of the cornea.


Options:
A: Inclusion Criteria:

* Infectious bacterial or fungal keratitis with : size \> 2mm or within the central corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber.
* Being major responsible.
* Agreement in writing to participate in the study.
* Being affiliated to a national insurance scheme.

Exclusion Criteria:

* Present an infectious keratitis without all the previous criteria.
* Herpes or acanthamoeba keratitis
* preperforated or perforated cornea.

General criteria:

* Pregnant woman.
* Minors(miners).
* Adults under guardianship.
* Patient can not be followed during 3 necessary months.
* French speaking patient.
* Unaffiliated patient in a national insurance scheme.
* HIV infected patients
B: Inclusion Criteria:

* Ulcer size more than 5 mm
* Ulcer depth upto 70% of stromal depth
* Corneal thickness of 400 microns and above

Exclusion Criteria:

* Corneal thickness of below 400 microns
* Ulcers involving the limbus
* Pregnant women
* Children below the age of 18 years
C: Inclusion Criteria:

* Candidate for KPro type I
* Capacity to give written consent
* Ability to be followed for the duration of the study

Exclusion Criteria:

* Participation in another interventional study
* Failure to wear a therapeutic contact lens due to abnormalities of the eyelids.
* Inability to give written consent

Contraindications to the KPro type I:

* Severe dryness with keratinization of the ocular surface
* Intraocular tumor
* Terminal glaucoma
* Inoperable retinal detachment
* Phthisis bulbi
D: Inclusion Criteria:

* Documented progressive KC (by Pentacam and/or corneal topography imaging).
* A clear central cornea.
* A minimal corneal thickness of ≥ 400 µm at the thinnest corneal location (Pentacam imaging).
* Minimal Snellen corrected distance visual acuity of ≥ 0.4.
* Patient age of ≥ 18 years.

For this research study, the inclusion parameters will be the same as mentioned above, with the following additional inclusion criteria:

* Documented progression of KC, as demonstrated by anterior segment imaging and/or corneal topography:

  o Defined an increase in maximal keratometry, steepest keratometry, mean keratometry or topographic cylinder value by ≥ 0.5 D over the previous 6 months and/or a decrease in thinnest pachymetry
* Documented progression of KC defined by increase in refractive cylinder of ≥ 0.5 D over the previous 6 months

Exclusion Criteria:

* Presence of corneal scars.
* History of epithelial healing problems.
* Presence of previous ocular infection (such as herpes keratitis).
* Patients who are pregnant and/or breastfeeding.

Answer: A